Not Yet RecruitingNot Applicable

Ambispective Validation of the Odesa Criteria 2026 (OC26): A Flexible Point-Based System for Diagnosis of Autoimmune Pancreatitis.

82 participantsStarted 2026-05-01

Plain-language summary

Approval Number protocol 020237 Board Name Ethics Committee of the Military Medical Clinical Center of the Southern Region. Board Affiliation Military Medical Clinical Center of the Southern Region, Ukraine. Board Contact Information Phone: +380 (50) 316-10-54)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults (≥18 years) undergoing evaluation for suspected autoimmune pancreatitis. * Availability of clinical, serological, imaging, and/or histological data required for OC26 scoring. * Ability to provide informed consent (for prospective participants). Exclusion Criteria: * Confirmed alternative diagnosis explaining pancreatic findings (e.g., pancreatic cancer, acute pancreatitis of other etiology). * Incomplete diagnostic data preventing OC26 scoring. * Prior pancreatic surgery altering diagnostic interpretation.

What they're measuring

Diagnostic accuracy of the Odesa Criteria 2026 (OC26) for autoimmune pancreatitis

Timeframe: At completion of baseline diagnostic workup

Trial details

NCT IDNCT07536841

SponsorMilitary Medical Clinical Center of the Southern Region, Ukraine

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-10-01

Contact for this trial

Oleg Dovbenko, MD, PhD

+380682539685 dovbenko2015@hotmail.com

View on ClinicalTrials.gov More Autoimmune Pancreatitis trials